Plasminogen activator inhibitor type 1 and tissue inhibitor of metalloproteinases-2 increase after arterial injury in rats

Circulation Research

Volumn 80, Issue 4, 1997, Pages 490-496

  Hasenstab, David ^a   Forough, Reza ^b   Clowes, Alexander W ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

arterial injury; plasminogen activator inhibitor type 1; protease; smooth muscle cell; tissue inhibitor of metalloproteinases 2

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE INHIBITOR OF METALLOPROTEINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAROTID ARTERY ANOMALY; CONTROLLED STUDY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 0030898204     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.80.4.490     Document Type: Article

References (40)

1. Ross R. The pathogenesis of atherosclerosis; a perspective for the 1990's, Nature. 1993;362:801-809.
2. Clowes AW, Clowes MM, Kirkman TR, Jackson CL, Au YPT, Kenagy R. Heparin inhibits the expression of tissue-type plasminogen activator by smooth muscle cells in injured rat carotid artery. Circ Res. 1992;70:1128-1136.
3. Jackson CL, Reidy MA, The role of plasminogen activation in smooth muscle migration after arterial injury. Ann N Y Acad Sci. 1992;667:141-150.
4. Zempo N, Kenagy RD, Au YPT, Bendeck M, Clowes MM, Reidy MA, Clowes AW. Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery, J Vasc Surg. 1994;20:209-217.
5. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res. 1994;75:539-545.
6. Pauly RR, Passaniti A, Bilato C, Monticone R, Cheng L, Papadopoulos N, Gluzband YA, Smith L, Weinstein C, Lakatta EG, Crow MT, Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res. 1994;75:41-54.
7. Moscatelli D, Rifkin DB. Membrane and matrix localization of proteinases: a common theme in tumor cell invasion and angiogenesis. Biochim Biophys Acta. 1988;948:67-85.
8. Stettler-Stevenson WG, Liotta LA, Kleiner DE. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis, FASEB J. 1993;7:1434-1441.
9. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury. Lab Invest. 1983;49:327-333.
10. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1986;162:156-159.
11. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989:7.43.
12. Church GM, Gilbert W. Genomic sequencing, Proc Natl Acad Sci U S A. 1984;81:1991-1995.
13. Zeheb R, Gelehrter TD. Cloning and sequencing of cDNA for the rat plasminogen activator inhibitor-1. Gene. 1988;73:459-468.
14. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989:10.6.
15. Dean DD, Schwartz Z, Muniz OE, Gomez R, Swain LD, Howell DS, Boyan BD. Matrix vesicles are enriched in metalloproteinases that degrade proteoglycans, Calcif Tissue Int. 1992;50:342-349.
16. Laemmli UK. Cleavage of structural proteins during the assembly of the head bactcriophage T4. Nature. 1970;227:680-685.
17. Ginsburg D, Zeheb R, Yang AY, Rafferty UM, Andreasen PA, Nielsen L, Dano K, Lebo RV, Gelehrter TD. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. Clin invest. 1986;78:1673-1680.
18. Schneiderman JA, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries, Proc Natl Acad Sci U S A. 1992;89:6998-7002.
19. Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY, Bachmann F, Kruithof EKO. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb. 1993;13:1090-1100.
20. Liotta LA, Steeg PS, Stettler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991;64:327-336.
21. Lang IM, Marsh JJ, Olman MA, Moser KM, Loskutoff DJ, Schleef RR. Expression of type l plasminogen activator inhibitor in chronic pulmonary thromboemboli. Circulation. 1994;89:2715-2721.
22. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling, FASEB J. 1991;5:2145-2154.
23. Overall CM. Regulation of tissue inhibitor of matrix metalloproteinase expression, Ann N Y Acad Sci. 1994;732:51-64.
24. Salo T, Makela M, Kylmanieme M, Autio-Harmainen H, Larjava H. Expression of matrix metalloproteinase-2 and -9 during early human wound healing. Lab Invest. 1994;70:176-182.
25. Talhouk RS, Bissell MJ, Werb Z. Coordinated expression of extracellular matrix-degrading proteinases and their inhibitors regulates mammary epithelial function during involution, J Cell Biol. 1992;118:1271-1282.
26. Lala PK, Graham CH. Mechanisms of trophoblast invasiveness and their control; the role of proteases and protease inhibitors. Cancer Metastasis Rev. 1990;9:369-379.
27. Brenner CA, Adler RR, Rappolee DA, Pederson RA, Werb Z. Genes for extracellular matrix-degrading metalloproteinases and their inhibitor, TIMP, are expressed during early mammalian development. Genes Dev. 1989;3:848-859.
28. Sperti G, van Leeuwen RTJ, Quax PHA, Maseri A, Kluft C. Cultured rat aortic vascular smooth muscle cells digest naturally produced extracellular matrix: involvement of plasminogen-dependent and plasminogen-independent pathways. Circ Res. 1992;71:385-392.
29. Thornton AJ, Bruzdzinski CJ, Raper SE, Gelehrter TD. Plasminogen activator inhibitor-1 is an immediate early response gene in regenerating rat liver. Cancer Res. 1994;54:1337-1343.
30. Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. J Clin Invest, 1991;88:1346-1353.
31. Reilly CF, McFall RC. Platelet derived growth factor and transforming growth factor-beta regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells. J Biol Chem. 199l;266:9419-9427.
32. Seiffert D, Mimuro J, Schleef RR, Loskutoff DJ, Interactions between type 1 plasminogen activator inhibitor, extracellular matrix and vitronectin. Cell Differ Dev. 1990;32:287-292.
33. Prins MH, Hirsh J. A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism. Arch Intern Med. 1991;151:1721-1731.
34. Mc Donnell S, Matrisian LM. Stromelysin in tumor progression and metastasis. Cancer Metastasis Rev. 1990;9:305-319.
35. Stettler-Stevenson WG, Brown PD, Onisto M, Levy AT, Liotta LA. Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues, J Biol Chem. 1990;265:13933-13938.
36. Shimizu S, Malik K, Sejima H, Kishi J, Hayakawa T, Koiwai O. Cloning and sequencing of the cDNA encoding a mouse tissue inhibitor of metalloproteinase-2, Gene. 1992;114:291-292.
37. Leco KJ, Hayden LJ, Sharma RR, Rocheleau H, Greenberg AH, Edwards DR. Differential regulation of TIMP-1 and TIMP-2 mRNA expression in normal and Ha-ras-transformed murine fibroblasts. Gene. 1992;117:209-217.
38. Testa JE. Loss of the metastatic phenotype by a human epidermoid carcinoma cell line, HEp-3, is accompanied by increased expression of tissue inhibitor of metalloproteinase 2. Cancer Res. 1992;52:5597-5603.
39. Khokha R, Waterhouse P, Yagel S, Lala PK, Overall CM, Norton G, Denhardt DT. Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science. 1989;243:947-950.
40. Forough R, Hasenstab D, Koyama N, Lea H, Clowes M, Clowes AW. Generating antibodies against secreted proteins using vascular smooth muscle cells transduced with replication-defective retrovirus. Biotecchniques. 1996;20:694-701.